0001493152-23-028587.txt : 20230814 0001493152-23-028587.hdr.sgml : 20230814 20230814164846 ACCESSION NUMBER: 0001493152-23-028587 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230814 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardion Health Sciences, Inc. CENTRAL INDEX KEY: 0001642375 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474428421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38861 FILM NUMBER: 231171485 BUSINESS ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 BUSINESS PHONE: (800) 873-5141 MAIL ADDRESS: STREET 1: 2925 RICHMOND AVENUE STREET 2: SUITE 1200 CITY: HOUSTON STATE: TX ZIP: 77098 FORMER COMPANY: FORMER CONFORMED NAME: Guardion Health Sciences, LLC DATE OF NAME CHANGE: 20150513 8-K 1 form8-k.htm
0001642375 false 0001642375 2023-08-14 2023-08-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or Section 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): August 14, 2023

 

GUARDION HEALTH SCIENCES, INC.

(Exact name of registrant as specified in its charter)

 

Delaware   001-38861   47-4428421

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

2925 Richmond Avenue, Suite 1200

Houston, Texas 77098

(Address of principal executive offices, including zip code)

 

Registrant’s telephone number, including area code: (800) 873-5141

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, par value $0.001 per share   GHSI   The Nasdaq Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On August 14, 2023, Guardion Health Sciences, Inc. (the “Company”) issued a press release announcing financial results for the three months and six months ended June 30, 2023. The text of the press release is furnished as Exhibit 99.1 to this current report.

 

The information in this Item 2.02 and Exhibit 99.1 hereto shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits.

 

Exhibit No.   Exhibit
99.1   Press release dated August 14, 2023
104   Cover Page Interactive Data File (embedded within the XBRL document)

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  GUARDION HEALTH SCIENCES, INC.
Date: August 14, 2023    
  By: /s/ Jan Hall
  Name: Jan Hall
  Title: Chief Executive Officer

 

 3 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

Guardion Health Sciences Announces Financial Results for the Three Months and Six Months Ended June 30, 2023

 

Viactiv® Product Line Total Revenue Increased Approximately 6% for the Six Months Ended June 30, 2023, as Compared to the Six Months Ended June 30, 2022; Robust Growth in Amazon Sales Channel Demonstrates Positive Results of Company’s Focus on eCommerce Initiatives

 

HOUSTON, TEXAS – August 14, 2023 (GLOBE NEWSWIRE) – Guardion Health Sciences, Inc. (Nasdaq: GHSI) (“Guardion” or the “Company”), a clinical nutrition company that offers a portfolio of science-based, clinically-supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients, announced its financial results for the three months and six months ended June 30, 2023. The Company also provided a corporate update to stockholders.

 

Financial highlights for the three months and six months ended June 30, 2023 include the following (all common share and per share amounts shown below have been adjusted to reflect the 1-for-50 reverse stock split effective January 6, 2023):

 

  ● Total revenue was $2,789,817 for the three months ended June 30, 2023, as compared to $3,275,213 for the three months ended June 30, 2022, a decrease of $485,396 or 14.8%.The decrease in total revenue was driven by reduced sales of the Viactiv® product line, which accounted for approximately 97% and 97% of the Company’s total revenue for the three months ended June 30, 2023 and 2022, respectively.Shipments of Viactiv® to retail customers were delayed in the month of June 2023 due to the short-term impact of a third-party warehouse expansion, which was fully resolved in July 2023. eCommerce logistics were unaffected by this issue.  Amazon net sales for the three months ended June 30, 2023, increased by approximately 334.3% as compared to the three months ended June 30, 2022 and by approximately 124.3% as compared to the three months ended March 31, 2023.
     
  ● Gross profit was $1,249,268 for the three months ended June 30, 2023, as compared to $1,399,544 for the three months ended June 30, 2022, a decrease of $150,276 or 10.7%.The reduction in gross profit was primarily attributable to the decrease in sales from the Viactiv® product line.
     
  ● Gross margin for the three months ended June 30, 2023 was 44.8%, as compared to 42.7% for the three months ended June 30, 2022, an increase of 4.9%, which was driven primarily by an inventory reserve recorded in 2022.
     
  ● Total operating expenses for the three months ended June 30, 2023 were $2,261,914, as compared to $3,111,122 for the three months ended June 30, 2022, a decrease of $849,208 or 27.3%.The variance was attributable to a combination of factors, including the amortization of intangible assets in 2022 that was no longer occurring in 2023 and reduced payroll expense and lower executive stock compensation expense.

 

 1 

 

 

  ● Loss from operations for the three months ended June 30, 2023 decreased to $(1,012,646), as compared to $(1,711,578) for the three months ended June 30, 2022, a reduction of $698,932 or 40.8%.
     
  ● As a result of the aforementioned factors, and also including the non-cash gain (loss) from the change in fair value of the warrant derivative liability of $(255,300) and $5,357,600 for the three months ended June 30, 2023 and 2022, respectively, net loss was $(1,172,411) for the three months ended June 30, 2023, as compared to net income of $3,655,637 for the three months ended June 30, 2022.
     
  ● Basic and diluted net loss for the three months ended June 30, 2023 was $(0.93) per share, as compared to basic and diluted net income of $2.97 per share for the three months ended June 30, 2022, based on 1,267,340 weighted average common shares outstanding in 2023 and 1,231,063 weighted average common shares outstanding in 2022.

 

Financial highlights for the six months ended June 30, 2023 include the following:

 

  ● Total revenue was $5,975,506 for the six months ended June 30, 2023, as compared to $5,659,832 for the six months ended June 30, 2022, an increase of $315,674 or 5.6%.The increase in total revenue was driven by increased sales of the Viactiv® product line, which accounted for approximately 97% and 96% of the Company’s total revenue for the six months ended June 30, 2023 and 2022, respectively.  Shipments of Viactiv® to retail customers were delayed in the month of June 2023 due to the short-term impact of a third-party warehouse expansion, which was fully resolved in July 2023. eCommerce logistics were unaffected by this issue.  Amazon net sales for the six months ended June 30, 2023 increased by approximately 647.8% as compared to the six months ended June 30, 2022.
     
  ● Gross profit was $2,584,570 for the six months ended June 30, 2023, as compared to $2,496,001 for the six months ended June 30, 2022, an increase of $88,569 or 3.5%.The increase in gross profit was primarily attributable to the increase in sales from the Viactiv® product line.
     
  ● Gross margin for the six months ended June 30, 2023 was 43.3%, as compared to 44.1% for the six months ended June 30, 2022, a decrease of 0.8%, which was driven primarily by higher short-term fulfillment costs to accelerate initial product setup on Amazon in the three months ended March 31, 2023. Amazon fulfillment costs were lower for the three months ended June 30, 2023, as compared to the three months ended March 31, 2023.
     
  ● Total operating expenses for the six months ended June 30, 2023 were $5,061,223, as compared to $6,827,627 for the six months ended June 30, 2022, a decrease of $1,766,404 or 25.9%. The variance was attributable to a combination of factors, including the amortization of intangible assets in 2022, reduced payroll expense, insurance, and professional fees and consulting fees.

 

 2 

 

 

  ● Loss from operations for the six months ended June 30, 2023 decreased to $(2,476,653), as compared to $(4,331,626) for the six months ended June 30, 2022, a reduction of $1,854,973 or 42.8%.
     
  ● Basic and diluted net loss for the six months ended June 30, 2023 was $(0.50) per share, as compared to basic and diluted net loss of $(1.63) per share for the six months ended June 30, 2022, based on 1,267,340 weighted average common shares outstanding in 2023 and 1,009,243 weighted average common shares outstanding in 2022.
     
  ● Cash used in operations for the six months ended June 30, 2023 was $2,285,712, as compared to $4,800,765 for the six months ended June 30, 2022.
     
  ● As of June 30, 2023, the Company had unrestricted cash and cash equivalents of $8,365,987 and net working capital (excluding the current portion of the warrant derivative liability) of $11,993,202.

 

Additional significant events that occurred during the three months and six months ended June 30, 2023 and subsequently included the following:

 

  ● Alantra LLC was retained as the Company’s exclusive financial advisor to implement a strategic review to solicit and evaluate alternatives to maximize stockholder value in the near-term, which review is on-going.
     
  ● Jan Hall was appointed President and CEO, effective June 19, 2023, replacing Bret Scholtes.
     
  ● Katie Cox was appointed as Chief Accounting Officer, effective July 25, 2023, replacing Jeffrey Benjamin.

 

Jan Hall, Guardion’s recently-appointed President and Chief Executive Officer, commented, “I am truly excited to be able to join the Guardion team as its President and Chief Executive Officer. Based on my initial review, I believe that the Viactiv business has the potential to grow by focusing on powerful brand messaging with science-based claims that rank highest for shoppers’ purchase intent. We believe that we can deliver this messaging with an emotional hook that connects with the values, needs and aspirations of our target consumers. We recently implemented a Bold Age advertising campaign for the Viactiv calcium chews that has already seen positive results, as compared with industry metrics and prior Viactiv campaigns. As we learn more from in-market performance, we will continue to refine and optimize the creative aspects of our marketing campaigns. Effective advertising, combined with targeted marketing initiatives, product innovations in existing and new product segments, plus expanded retail and online distribution, will be the engine of future growth to make Viactiv a broad-based destination health and wellness brand with a foundation in clinically supported efficacy.”

 

 3 

 

 

“We have seen the initial results of management’s continuing efforts to improve operating performance during the first half of 2023, reflected in improved operating margins in the second quarter of 2023 and a reduced cash burn. The focus on efficiency will be ongoing in the second half of the year.”

 

“We continue to believe that the Company remains undervalued in the public market, specifically with regard to the clinical nutrition platform and the brand that we are building. Our work with Alantra, LLC (“Alantra”), our exclusive financial advisor, is underway as we conduct our strategic review to solicit and evaluate alternatives to maximize stockholder value in the near-term, which could range from a sale of the Company, sale of the Viactiv brand, merger, asset acquisition, reverse acquisition, or other potential strategic transaction. As this process evolves, we anticipate providing updates to our stockholders as developments warrant.”

 

“In the meantime, we believe our market position and the extendability of the Viactiv brand, combined with our current operating business strategy, provide us with a viable platform from which to leverage our resources to continue our efforts to grow operations, improve financial performance and maximize stockholder value,” concluded Ms. Hall.

 

Financial Results

 

Additional information with respect to the Company’s business, operations and financial condition as of and for the three months and six months ended June 30, 2023 is contained in the Company’s Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023, which has been filed with the U.S. Securities and Exchange Commission (the “SEC”) at www.sec.gov.

 

About Guardion Health Sciences, Inc.

 

Guardion Health Sciences, Inc. (Nasdaq: GHSI), is a clinical nutrition company that offers a portfolio of science-based, clinically supported products designed to support the health needs of consumers, healthcare professionals and providers and their patients. Information and risk factors with respect to Guardion and its business may be obtained in the Company’s filings with the SEC at www.sec.gov.

 

 4 

 

 

Forward-Looking Statement Disclaimer

 

With the exception of the historical information contained in this news release, the matters described herein may contain “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements contain information about our expectations, beliefs, plans or intentions regarding our product development and commercialization efforts, research and development efforts, business, financial condition, results of operations, strategies or prospects, and other similar matters. Statements preceded by, followed by or that otherwise include the words “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” “hopes” and similar expressions or future or conditional verbs such as “will,” “should,” “would,” “may” and “could” are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing.

 

These statements are based on management’s current expectations and assumptions about future events, which are inherently subject to uncertainties, risks and changes in circumstances that are difficult to predict, and involve unknown risks and uncertainties that may individually or materially impact the matters discussed herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company’s ability to raise sufficient financing to fund its business plan, the impact of the Company’s exploration of strategic alternatives, any replacement and integration of new management team members, the implementation of new financial, management, accounting and business software systems, the identification and integration of possible acquisition targets and suitors, the impact of the Covid-19 pandemic, supply chain disruptions, inflation and a potential recession on the Company’s business, operations and the economy in general, the Company’s ability to successfully develop and commercialize its proprietary products and technologies, and the Company’s ability to maintain compliance with Nasdaq’s continued listing requirements.

 

Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

 

Investor Relations Contact:

 

CORE IR

Scott Arnold

516-222-2560

scotta@coreir.com

 

Media Relations Contact:

 

Jules Abraham

Director of Public Relations

CORE IR

917-885-7378

julesa@coreir.com

 

 5 

 

 EX-101.SCH 3 ghsi-20230814.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ghsi-20230814_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ghsi-20230814_pre.xml XBRL PRESENTATION FILE XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Cover
Aug. 14, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Aug. 14, 2023
Entity File Number 001-38861
Entity Registrant Name GUARDION HEALTH SCIENCES, INC.
Entity Central Index Key 0001642375
Entity Tax Identification Number 47-4428421
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 2925 Richmond Avenue
Entity Address, Address Line Two Suite 1200
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77098
City Area Code (800)
Local Phone Number 873-5141
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.001 per
Trading Symbol GHSI
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 7 form8-k_htm.xml IDEA: XBRL DOCUMENT 0001642375 2023-08-14 2023-08-14 iso4217:USD shares iso4217:USD shares 0001642375 false 8-K 2023-08-14 GUARDION HEALTH SCIENCES, INC. DE 001-38861 47-4428421 2925 Richmond Avenue Suite 1200 Houston TX 77098 (800) 873-5141 false false false false Common Stock, par value $0.001 per GHSI NASDAQ true false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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

JQ"(6,P$ "(" / M " :@0 !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4 " 6 MA@Y7)!Z;HJT #X 0 &@ @ $($@ >&PO7W)E;',O=V]R M:V)O;VLN>&UL+G)E;'-02P$"% ,4 " 6A@Y799!YDAD! #/ P $P M @ 'M$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 "0 ) + #X" W% ! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://guardionhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports form8-k.htm ex99-1.htm ghsi-20230814.xsd ghsi-20230814_lab.xml ghsi-20230814_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "form8-k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "form8-k.htm" ] }, "labelLink": { "local": [ "ghsi-20230814_lab.xml" ] }, "presentationLink": { "local": [ "ghsi-20230814_pre.xml" ] }, "schema": { "local": [ "ghsi-20230814.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] } }, "elementCount": 59, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2023": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "GHSI", "nsuri": "http://guardionhealth.com/20230814", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://guardionhealth.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "span", "p", "body", "html" ], "baseRef": "form8-k.htm", "contextRef": "AsOf2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentDescription": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Description of changes contained within amended document.", "label": "Amendment Description" } } }, "localname": "AmendmentDescription", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stringItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AnnualInformationForm": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.", "label": "Annual Information Form" } } }, "localname": "AnnualInformationForm", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_AuditedAnnualFinancialStatements": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.", "label": "Audited Annual Financial Statements" } } }, "localname": "AuditedAnnualFinancialStatements", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CountryRegion": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Region code of country", "label": "Country Region" } } }, "localname": "CountryRegion", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentAccountingStandard": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.", "label": "Document Accounting Standard" } } }, "localname": "DocumentAccountingStandard", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "accountingStandardItemType" }, "dei_DocumentAnnualReport": { "auth_ref": [ "r11", "r13", "r14" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an annual report.", "label": "Document Annual Report" } } }, "localname": "DocumentAnnualReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentPeriodStartDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.", "label": "Document Period Start Date" } } }, "localname": "DocumentPeriodStartDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentRegistrationStatement": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a registration statement.", "label": "Document Registration Statement" } } }, "localname": "DocumentRegistrationStatement", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentShellCompanyEventDate": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Date of event requiring a shell company report.", "label": "Document Shell Company Event Date" } } }, "localname": "DocumentShellCompanyEventDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentShellCompanyReport": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.", "label": "Document Shell Company Report" } } }, "localname": "DocumentShellCompanyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r15" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Documents incorporated by reference.", "label": "Documents Incorporated by Reference [Text Block]" } } }, "localname": "DocumentsIncorporatedByReferenceTextBlock", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "textBlockItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine3": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 3 such as an Office Park", "label": "Entity Address, Address Line Three" } } }, "localname": "EntityAddressAddressLine3", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.", "label": "Entity Bankruptcy Proceedings, Reporting Current" } } }, "localname": "EntityBankruptcyProceedingsReportingCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r19" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Elected Not To Use the Extended Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r16" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityPrimarySicNumber": { "auth_ref": [ "r14" ], "lang": { "en-us": { "role": { "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.", "label": "Entity Primary SIC Number" } } }, "localname": "EntityPrimarySicNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "sicNumberItemType" }, "dei_EntityPublicFloat": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.", "label": "Entity Public Float" } } }, "localname": "EntityPublicFloat", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "monetaryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_EntityVoluntaryFilers": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.", "label": "Entity Voluntary Filers" } } }, "localname": "EntityVoluntaryFilers", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_EntityWellKnownSeasonedIssuer": { "auth_ref": [ "r17" ], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.", "label": "Entity Well-known Seasoned Issuer" } } }, "localname": "EntityWellKnownSeasonedIssuer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "yesNoItemType" }, "dei_Extension": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Extension number for local phone number.", "label": "Extension" } } }, "localname": "Extension", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_NoTradingSymbolFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a security having no trading symbol.", "label": "No Trading Symbol Flag" } } }, "localname": "NoTradingSymbolFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "trueItemType" }, "dei_OtherReportingStandardItemNumber": { "auth_ref": [ "r13" ], "lang": { "en-us": { "role": { "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.", "label": "Other Reporting Standard Item Number" } } }, "localname": "OtherReportingStandardItemNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "otherReportingStandardItemNumberItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r8" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_Security12gTitle": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(g) registered security.", "label": "Title of 12(g) Security" } } }, "localname": "Security12gTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SecurityReportingObligation": { "auth_ref": [ "r9" ], "lang": { "en-us": { "role": { "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.", "label": "Security Reporting Obligation" } } }, "localname": "SecurityReportingObligation", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "securityReportingObligationItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r10" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r18" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://guardionhealth.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r10": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r11": { "Name": "Form 10-K", "Number": "249", "Publisher": "SEC", "Section": "310", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r12": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r13": { "Name": "Form 20-F", "Number": "249", "Publisher": "SEC", "Section": "220", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r14": { "Name": "Form 40-F", "Number": "249", "Publisher": "SEC", "Section": "240", "Subsection": "f", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r15": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r16": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r17": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r18": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r19": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-23", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "g", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12, 13, 15d", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r7": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r8": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r9": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "15", "Subsection": "d", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001493152-23-028587-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-028587-xbrl.zip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end